Tocagen Inc. (NASDAQ:TOCA) and Clearside Biomedical Inc. (NASDAQ:CLSD) compete with each other in the Biotechnology sector. We will analyze and compare their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tocagen Inc. 18.04M 13.96 40.19M -2.02 0.00
Clearside Biomedical Inc. N/A 919.97 77.67M -2.66 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Tocagen Inc. and Clearside Biomedical Inc.

Profitability

Table 2 hightlights the return on assets, net margins and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Tocagen Inc. -222.78% -71.6% -46.1%
Clearside Biomedical Inc. 0.00% -142.5% -102.8%

Liquidity

The current Quick Ratio of Tocagen Inc. is 5.8 while its Current Ratio is 5.8. Meanwhile, Clearside Biomedical Inc. has a Current Ratio of 4.6 while its Quick Ratio is 4.6. Tocagen Inc. is better positioned to pay off its short-term and long-term debts than Clearside Biomedical Inc.

Insider and Institutional Ownership

Roughly 31% of Tocagen Inc. shares are owned by institutional investors while 69.8% of Clearside Biomedical Inc. are owned by institutional investors. 7.6% are Tocagen Inc.’s share owned by insiders. Competitively, insiders own roughly 0.3% of Clearside Biomedical Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Tocagen Inc. -1.47% 5.39% 3.76% 31.85% 19.68% 24%
Clearside Biomedical Inc. -2.04% -34.25% -78.02% -84.98% -76.77% -79.43%

For the past year Tocagen Inc. had bullish trend while Clearside Biomedical Inc. had bearish trend.

Summary

Tocagen Inc. beats Clearside Biomedical Inc. on 7 of the 9 factors.

Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient’s immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The companyÂ’s lead product candidate is Toca 511 & Toca FC that is in Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial for patients with recurrent high grade glioma (HGG). It is also developing Toca 511 & Toca FC in a Phase 1b clinical trial for metastatic cancers, including colorectal, pancreatic, breast, lung, melanoma, and renal. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets, such as the checkpoint protein PD-L1. Tocagen Inc. was founded in 2007 and is headquartered in San Diego, California.

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops first-in-class drug therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion (RVO); and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase I/II clinical trial for diabetic macular edema (DME). The companyÂ’s pre-clinical development program for axitinib for the treatment of wet age-related macular degeneration (wet AMD). Clearside Biomedical, Inc. has a collaboration agreement with Santen Pharmaceutical Co., Ltd. to develop compounds for suprachoroidal space injection that are designed to treat DME, wet AMD, and RVO, as well as to reduce elevated intraocular pressure associated with glaucoma for a sustained period of time. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *